Active ingredientPralsetinibCat. No. P-P163-001CAS 2097132-94-8Family · Pharmaceutical analytical standards
Pralsetinib
A selective RET kinase inhibitor, approved in the United States in September 2020 for RET fusion-positive non-small cell lung cancer and in December of the same year for RET-altered thyroid cancers. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?The name of its target, RET, stands for 'rearranged during transfection': in 1985 the gene was found rearranged in mouse cells after DNA from human lymphoma cells had been transferred into them.
Go to the active ingredient →Active ingredientPralsetinibCat. No. P-P163-001CAS 2097132-94-8
Isotopically labelledPralsetinib (BLU667)-13C-d3Cat. No. P-P163-002
ImpurityPralsetinib Impurity 1Cat. No. P-P163-004CAS 2778223-51-9
ImpurityPralsetinib Impurity 2Cat. No. P-P163-005CAS 2778223-52-0
ImpurityPralsetinib Impurity 3 HydrochlorideCat. No. P-P163-006CAS 2097133-17-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.